Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics (CRNX) Q2 Revenue Jumps 150%
10:57pm, Thursday, 07'th Aug 2025
Crinetics (CRNX) Q2 Revenue Jumps 150%
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
06:56pm, Thursday, 07'th Aug 2025
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $0.94 per share a year ago.
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 07'th Aug 2025
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progres
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
11:01am, Thursday, 31'st Jul 2025
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
08:00am, Friday, 11'th Jul 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:28pm, Thursday, 10'th Jul 2025
SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qual
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patie
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
08:00am, Monday, 16'th Jun 2025
SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025,
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:29pm, Tuesday, 10'th Jun 2025
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qual
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
08:00am, Friday, 23'rd May 2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taki
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 12'th May 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualif
Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript
01:50pm, Saturday, 10'th May 2025
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Thursday, 08'th May 2025
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $0.93 per share a year ago.
